SYNTERA BIORISK
SpeciesSmall ruminantsReleaseFrance · 2026-09-07
  1. Global Overview
  2. Europe
  3. France
  4. Sheep pox and goat pox
Country–disease dossierFrance · Sheep pox and goat pox
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
France cross-disease portfolio FRANCE DISEASE PROFILE · LINKED WORKSPACE

Sheep pox and goat pox

Official evidence, 18-region exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine feverofficially freeHighly pathogenic avian influenzacurrent outbreak low national risk levelBluetongueenzootic active btv3Bovine tuberculosisofficially free with residual outbreaksFoot-and-mouth diseaseofficially freePeste des petits ruminantsofficially freeNewcastle diseaseno current event in registered sourceClassical swine feverofficially freeSheep pox and goat poxofficially freeLumpy skin diseaseno active outbreak vaccination controls continueBovine viral diarrhoeaendemic control programmeJohne's diseaseendemic control framework current prevalence unavailableEpizootic haemorrhagic diseaseno current season outbreak after recent epidemic
Official disease status · 2026-05-27

Sheep pox and goat pox

France is free from sheep pox and goat pox; the diseases circulate in parts of south-eastern Europe.

Selected geography
France
Susceptible livestock
7.85m
Evidence nature
Observed / official
Exposure layer

France · susceptible livestock

IGN COG 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

France

sheep6.46m
goats1.39m

Agreste SAA 2025 provisional observations; source grain retained.

Official signal at selected grain

No numeric national event series is published in the registered official source. The status narrative remains available.

Observed economics · national/source scope
Observed direct loss · national
N/A
Published programme cost · source scope
N/A
Monetised trade effect
N/A

No compatible current France-specific direct-loss estimate is registered; no value is inferred.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Import safeguardsPlanning option retained for explicit activation in Scenario Lab
  2. 02Rapid diagnosticsPlanning option retained for explicit activation in Scenario Lab
  3. 03Holding depopulation and zoningPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

Category A rules require immediate eradication and total depopulation of confirmed infected holdings.

The registered official source documents controls but not a compatible France-wide monetised consequence.
Release principle: every France disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief